Approximately 70% of all breast cancers are due to hormone receptor (ER)-positive BCa. Currently, ER+ BCa diagnosed patients can be treated with hormone therapy via drugs, such as tamoxifen. However, this type of breast cancer can lead to reoccurrences many years after treatment. In this particular study, we have developed a new therapy by targeting metabolic signaling to overcome endocrine resistance in breast cancer.